User profiles for Alexander Alexandrov

Alexander Alexandrov

- Verified email at tu-berlin.de - Cited by 1599

Alexander I Alexandrov

- Verified email at weizmann.ac.il - Cited by 610

The stratosphere platform for big data analytics

A Alexandrov, R Bergmann, S Ewen, JC Freytag… - The VLDB Journal, 2014 - Springer
We present Stratosphere, an open-source software stack for parallel data analysis. Stratosphere
brings together a unique set of features that allow the expressive, easy, and efficient …

[HTML][HTML] Microscale fluorescent thermal stability assay for membrane proteins

AI Alexandrov, M Mileni, EYT Chien, MA Hanson… - Structure, 2008 - cell.com
Systematic efforts to understand membrane protein stability under a variety of different
solution conditions are not widely available for membrane proteins, mainly due to technical …

Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study

P Bogomolov, A Alexandrov, N Voronkova… - Journal of …, 2016 - Elsevier
Background & Aims The therapeutic option for patients with chronic hepatitis delta virus
infection (CHD) is limited to interferon alpha with rare curative outcome. Myrcludex B is a first-in-…

The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus

…, M Warlich, AW Lohse, JM Pollok, A Alexandrov… - Journal of …, 2013 - Elsevier
BACKGROUND & AIMS: Currently approved antivirals rarely cure hepatitis B virus (HBV)
infection. Therefore additional therapeutic strategies interfering with other viral replication steps …

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a …

…, WE Haefeli, M Dandri, A Alexandrov… - The Lancet Infectious …, 2023 - thelancet.com
Background Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV)
and hepatitis D virus infection. In July, 2020, bulevirtide 2 mg received conditional marketing …

First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B

…, A Carls, G Mikus, T Lehr, A Alexandrov… - Journal of …, 2016 - Elsevier
Background & Aims Myrcludex B is a first-in-class compound, which blocks entry of hepatitis
B and D virus into hepatocytes in vitro and in animal models. Based on the required …

Gluonts: Probabilistic and neural time series modeling in python

A Alexandrov, K Benidis, M Bohlke-Schneider… - Journal of Machine …, 2020 - jmlr.org
We introduce the Gluon Time Series Toolkit (GluonTS), a Python library for deep learning
based time series modeling for ubiquitous tasks, such as forecasting and anomaly detection. …

[HTML][HTML] Protein synthesis and quality control in aging

AS Anisimova, AI Alexandrov, NE Makarova… - Aging (Albany …, 2018 - ncbi.nlm.nih.gov
Aging is characterized by the accumulation of damage and other deleterious changes,
leading to the loss of functionality and fitness. Age-related changes occur at most levels of …

Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides

…, R Kunert, C Baum, I Choi, A Alexandrov… - Journal of …, 2004 - Am Soc Microbiol
As the limitations of antiretroviral drug therapy, such as toxicity and resistance, become
evident, interest in alternative therapeutic approaches for human immunodeficiency virus (HIV) …

[HTML][HTML] Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus

…, I Müller, F Brauer, G Brandenburg, A Alexandrov… - Molecular Therapy, 2007 - cell.com
Drug toxicity and viral resistance limit the long-term efficacy of antiviral drug treatment for
human immunodeficiency virus (HIV) infection. Thus, alternative therapies need to be explored. …